OPuS-2 study now enrolling patients
OPuS-2 is an 12 week study of BCX4161, an oral kallikrein inhibitor being studied for prevention of HAE attacks in patients with Type I and II HAE. This study is currently open to enrolling patients in the US, UK, and Germany, with planned clinical trial locations in Belgium, Canada, Hungary, Italy and France. If you [...]